Rosuvastatin Sprinkle Capsules and Tybost

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Cobicistat may increase the blood levels of rosuvastatin. This can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with rosuvastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with cobicistat may increase the plasma concentrations of rosuvastatin. The proposed mechanism is cobicistat inhibition of the OATP1B1-mediated hepatic uptake of rosuvastatin. In 10 healthy volunteers, administration of a single 10 mg dose of rosuvastatin in combination with a 150 mg dose each of cobicistat and elvitegravir increased mean rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) by 89% and 38%, respectively. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.

MANAGEMENT: Caution is advised if rosuvastatin is prescribed with cobicistat. The lowest starting dosage of rosuvastatin is recommended, then titrated as needed based on clinical response and tolerance. According to some authorities, the dose of rosuvastatin should not exceed 10 mg daily. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.

Rosuvastatin Sprinkle Capsules

Generic Name: rosuvastatin

Brand name: Crestor, Ezallor Sprinkle

Synonyms: Rosuvastatin

What is Rosuvastatin Sprinkle Capsules?

Tybost

Generic Name: cobicistat

Brand name: Tybost

Synonyms: n.a.

What is Tybost?